1. Background {#sec1-jcm-09-01657}
=============

Currently, the standard treatment for patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) is dual antiplatelet therapy (DAPT) with aspirin plus P2Y12 inhibitor \[[@B1-jcm-09-01657],[@B2-jcm-09-01657],[@B3-jcm-09-01657]\]. Compared with aspirin monotherapy, DAPT for 12 months reduces the risk of recurrent major ischemic events in patients with ACS \[[@B4-jcm-09-01657]\]. However, bleeding risk with DAPT is still a major concern. Bleeding risk is more important than ischemic risk in predicting clinical outcomes after PCI \[[@B5-jcm-09-01657]\]. Furthermore, with advanced drug-eluting stent (DES) and improved skills for optimal stent implantation, DAPT duration shortening is recommended. P2Y12 inhibitor monotherapy is suggested as an alternative antiplatelet strategy in patients undergoing PCI. Several clinical trials have been performed to compare the efficacy and safety of P2Y12 monotherapy with conventional DAPT after PCI \[[@B6-jcm-09-01657],[@B7-jcm-09-01657],[@B8-jcm-09-01657],[@B9-jcm-09-01657]\]. Among these studies, GLOBAL LEADERS and TWILIGHT trials have been performed in the West and have used ticagrelor monotherapy \[[@B6-jcm-09-01657],[@B7-jcm-09-01657]\]. Conversely, STOPDAPT-2 and SMART-CHOICE trials were performed in Japan and Korea, the majority of which used clopidogrel monotherapy (60% in STOPDAPT-2 and 77% in SMART-CHOICE) \[[@B8-jcm-09-01657],[@B9-jcm-09-01657]\]. These trials concluded that P2Y12 inhibitor monotherapy is noninferior or superior to conventional DAPT for ischemic events at 1-year follow-up after PCI, and the risk of major bleeding was similar or lower in the P2Y12 inhibitor monotherapy group. These clinical trials showed that early aspirin-free strategy with P2Y12 inhibitor monotherapy might be an alternative after PCI. Ticagrelor is a direct-acting antagonist of P2Y12 receptor and provides more potent platelet inhibition than does clopidogrel \[[@B10-jcm-09-01657]\]. The PLATO study showed that patients with ACS receiving DAPT with ticagrelor had significantly better cardiovascular outcomes than those receiving DAPT with clopidogrel \[[@B11-jcm-09-01657]\]. Ticagrelor was introduced to Taiwan in 2013 and gradually became the first-line P2Y12 inhibitor for ACS \[[@B12-jcm-09-01657]\]. Currently, clopidogrel is mainly used for patients with a high bleeding risk, such as old age, low body weight, concomitant use of oral anticoagulant, and prior major bleeding history \[[@B3-jcm-09-01657]\]. However, ticagrelor was not commonly used in Japan and Korea because of the bleeding risk involved. According to the data of 70,715 patients with ACS in the claims databases of the Korean National Health Insurance Service, ticagrelor was prescribed in only 16.1% of the patients \[[@B13-jcm-09-01657]\]. In 9684 patients with ACS who underwent PCI in the Korea Acute Myocardial Infarction Registry-National Institutes of Health (KAMIR-NIH) registry, the prescription rate of ticagrelor was 15.2%. \[[@B14-jcm-09-01657]\]. In Japan, the thienopyridine class of P2Y12 inhibitor, including standard-dose clopidogrel or reduced-dose prasugrel, is recommended as the first-line treatment in the ACS guideline \[[@B15-jcm-09-01657]\]. Ticagrelor is considered only in patients not suitable for thienopyridine \[[@B15-jcm-09-01657]\]. When P2Y12 inhibitor monotherapy is considered as an alternative antiplatelet strategy for patients with ACS, the results of whether clopidogrel or ticagrelor presents similar risk of ischemia and bleeding remain uncertain. Therefore, we designed this study to observe the clinical outcomes of patients with ACS who received PCI but could not complete DAPT course and hence received only P2Y12 inhibitor monotherapy. The efficacy and safety of clopidogrel versus ticagrelor were compared in these patients.

2. Methods {#sec2-jcm-09-01657}
==========

2.1. Study Population {#sec2dot1-jcm-09-01657}
---------------------

This was a multicenter, retrospective, observational study. From January 2014 to December 2018, the clinical and follow-up data of patients with ACS who received PCI during admission and were treated with either clopidogrel or ticagrelor monotherapy were collected retrospectively from 8 major teaching hospitals in Taiwan. The ACS diagnosis, including ST-segment elevation myocardial infarction (STEMI), non-STEMI, and unstable angina, depends on clinical presentation, changes in electrocardiogram, and elevation of cardiac biomarkers, and it was performed according to current guidelines by the cardiologists in charge. The inclusion criteria were as follows: men or women (1) aged ≥ 18 years, (2) who were hospitalized and survived to be discharged with ACS as a major diagnosis, (3) who were treated with PCI during admission, (4) who regularly followed up in an outpatient clinic for at least 1 year after discharge, and (5) for whom aspirin was stopped within 6 months after PCI and monotherapy was used with clopidogrel 75 mg daily or ticagrelor 90 mg twice daily. The exclusion criteria were patients with (1) life-threatening malignancy with life expectancy less than 1 year, (2) hematological disease with bleeding tendency, (3) treatment with immunosuppressive agents, (4) any condition or situation that in the opinion of the investigators might be unsuitable for this study. Clinical data including age, sex, vascular risk factors, previous disease history, PCI procedures, and medications used during admission and outpatient clinic visits were collected according to a predetermined protocol. The study was conducted according to the principles expressed in the Declaration of Helsinki and was approved by the Institutional Review Boards of the participating hospitals.

2.2. Follow-Up {#sec2dot2-jcm-09-01657}
--------------

All patients were followed up regularly after discharge for at least 1 year. The timing and reasons of aspirin discontinuation after PCI were recorded. P2Y12 inhibitor choice between clopidogrel and ticagrelor was at the discretion of the cardiologists in charge. The primary endpoint was the composite of all-cause mortality, recurrent ACS or unplanned revascularization, and stroke within 12 months after the index PCI. The secondary endpoint was the breakdown incidence of all-cause mortality, recurrent ACS or unplanned revascularization, and stroke. Recurrent ACS was defined as readmission to a hospital for new-onset unstable angina or acute myocardial infarction (MI) diagnosed according to the current guidelines. Unplanned revascularization was defined as any unplanned repeated PCI for previous target-vessel, target-lesion, or non--target-vessel revascularization or coronary artery bypass graft (CABG) after the index PCI procedure due to new-onset ischemic symptoms. An elective procedure was not included as an endpoint. Stroke was defined as a sudden onset of neurological deficits and fitting the definition of ischemic or hemorrhagic stroke. All patients with stroke underwent neuroimaging studies that were verified by neurologists. Each patient was followed up for 12 months after discharge or until primary endpoint occurrence. The safety endpoint was major bleeding, which was defined as the Bleeding Academic Research Consortium (BARC) type 3 and 5 bleedings \[[@B16-jcm-09-01657]\].

2.3. Statistical Analysis {#sec2dot3-jcm-09-01657}
-------------------------

Continuous variables are expressed as means ± standard deviations or medians with the 25th and 75th percentiles. Categorical variables are expressed as numbers and percentages. For comparison between patients with clopidogrel and ticagrelor monotherapy, a chi-square test for categorical variables and an unpaired Student's *t* test for continuous variables were used. Significance was set at *p* \< 0.05 (2-tailed). To account for any selection bias resulting from differences between clopidogrel and ticagrelor groups and to improve the overall representativeness of the sample population, an inverse probability of treatment weights (IPTW) propensity-score method was applied \[[@B17-jcm-09-01657],[@B18-jcm-09-01657]\]. The propensity-score weight was calculated as the inverse of the propensity score for each client. The Cox proportional-hazards models were then adjusted for differences in the treatment groups using IPTW derived from the propensity score (designated as IPTW models). The Cox models were further adjusted for covariates that remained imbalanced after weighting. Adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) were calculated. We used the same Cox proportional hazards model to estimate *p*-values for interaction in the subgroup analysis.

We estimated the sample size needed to compare the ticagrelor group and clopidogrel group for primary outcome in Cox regression model. We set type I error α to be 0.05 and power to be 0.8 and then used the event rates (0.10 and 0.16) of two groups and postulated hazard ratio for estimating sample size. Thus, a sample size of 241 subjects for ticagrelor group and 369 subjects for clopidogrel group had a reasonable power (0.8) in our study. SAS statistical package (version 9.4 for Windows; SAS Institute, Cary, NC, USA) was used for all analyses.

3. Results {#sec3-jcm-09-01657}
==========

From 1 January 2014 to 31 December 2018, a total of 610 patients with ACS (mean age: 70.4 ± 13.1 years; 72.1% men) who fulfilled the inclusion criteria were enrolled in this study. Among them, 28.5% had STEMI, 74.1% had multivessel disease, and 59.4% received DES. The duration (median and the 25th and 75th percentile) of aspirin treatment was 10 (1.0--43.0) days. Aspirin was discontinued within 1 month in 69.3% and within 1 to 3 months in 16.1% after PCI. [Table 1](#jcm-09-01657-t001){ref-type="table"} lists the reasons for early aspirin discontinuation. Bleeding (41.2%), including gastrointestinal (36.9%) and other site bleeding (5.3%), was the most common reason for aspirin discontinuation. The requirement of oral anticoagulation treatment (20%) was the second common cause. Among the patients, 369 (60.5%) and 241 (39.5%) were treated with clopidogrel and ticagrelor monotherapy, respectively. The aspirin treatment durations in the clopidogrel and ticagrelor groups were 9 (1.39--37.00) and 10 (1.00--55.00) days, respectively (*p* = 0.514). The proportion of patients with aspirin discontinuation because of bleedings was similar between the groups but that because of the requirement of oral anticoagulation treatment was higher in the clopidogrel group than in the ticagrelor group (28.5% vs. 7.1%, *p* \< 0.001; [Table 1](#jcm-09-01657-t001){ref-type="table"}).

Before propensity-score weighting, clopidogrel-treated patients were older and had a higher proportion of women, hypertension, dialysis, and atrial fibrillation than ticagrelor-treated patients. The proportion of STEMI, 3-vessel disease, use of bare-metal stent (BMS), and PCI procedures was similar between the groups ([Table 2](#jcm-09-01657-t002){ref-type="table"}). Moreover, the use of beta blocker, angiotensin-converting-enzyme inhibitor/angiotensin receptor blocker, and statin was similar. After propensity-score weighting, the clopidogrel and ticagrelor groups were well balanced in terms of all clinical characteristics and treatment (all *p* \> 0.1; [Table 2](#jcm-09-01657-t002){ref-type="table"}).

[Table 3](#jcm-09-01657-t003){ref-type="table"} presents the clinical outcomes of the study population during the 12-month follow-up. Overall, 84 patients reached the primary endpoint during the follow-up, with 57 (15.45%) and 27 (11.20%) in the ticagrelor and clopidogrel groups, respectively. After multivariate adjustment in the Cox model, a lower risk of the primary composite endpoint was associated with ticagrelor than with clopidogrel (aHR: 0.67, 95% CI: 0.49--0.93) ([Table 3](#jcm-09-01657-t003){ref-type="table"}). For the secondary endpoint, a significantly lower risk of recurrent ACS or unplanned revascularization was associated with ticagrelor than with clopidogrel (aHR: 0.46, 95% CI: 0.28--0.75). No significant difference in all-cause mortality was observed between the 2 groups. In the clopidogrel group, stroke occurred in 5 patients, ischemic stroke in 4, and hemorrhagic stroke in 1 patient. Furthermore, the risk of BARC 3 or 5 bleeding was similar. The effects of ticagrelor on the primary endpoint were consistent among the subgroups that were defined according to age, sex, medications, and comorbidities, except for patients with diabetes mellitus ([Figure 1](#jcm-09-01657-f001){ref-type="fig"}). Overall, 122 patients in the study cohort required oral anticoagulation, and 105 (86%) of them were in the clopidogrel group. To eliminate the influence of concomitant oral anticoagulation on clinical outcomes, we recalculated the data after excluding the 122 patients. However, ticagrelor still showed a significantly reduced risk of recurrent ACS or unplanned revascularization (aHR: 0.50, 95% CI: 0.29--0.86). BARC 3 or 5 bleeding occurred in 4.92% of the clopidogrel group and 3.13% of the ticagrelor group, and no significant difference was observed between the groups (aHR: 1.46, 95% CI: 0.65--3.29; [Table 4](#jcm-09-01657-t004){ref-type="table"}).

4. Discussion {#sec4-jcm-09-01657}
=============

Our study is the first investigation to compare the efficacy and safety of clopidogrel versus ticagrelor monotherapy in patients with ACS undergoing PCI. The main results indicated that ticagrelor-treated patients were associated with a lower risk of primary composite endpoint compared to clopidogrel. Moreover, ticagrelor did not show an increased risk of major bleeding.

Until now, 2 clinical trials have compared different antiplatelet monotherapies in patients with atherosclerotic cardiovascular disease. The CAPRIE trial compared aspirin and clopidogrel in 19,185 stable patients with a history of MI, ischemic stroke, or symptomatic peripheral artery disease (PAD) and found that clopidogrel slightly reduced ischemic events compared with aspirin, with no excess bleeding \[[@B19-jcm-09-01657]\]. The EUCLID trial compared clopidogrel versus ticagrelor in 13,885 patients with symptomatic PAD. In this study, only 29% and 18% of the enrolled patients had a history of coronary artery disease and MI, respectively. Furthermore, the trial showed that ticagrelor did not reduce the likelihood of the composite endpoint of death, MI, and ischemic stroke compared with clopidogrel. Moreover, the major bleeding risk defined by the Thrombolysis in Myocardial Infarction criteria was similar between the groups \[[@B20-jcm-09-01657]\]. So far, direct comparison has never been performed between different P2Y12 monotherapies in ACS. Our study demonstrated that recurrent ACS or unplanned revascularization during the first year after PCI can be better prevented with ticagrelor than with clopidogrel in patients with ACS. An Asian subgroup analysis of the PLATO study demonstrated that with aspirin as the background therapy, ticagrelor significantly improved the cardiovascular outcomes compared with clopidogrel in Asian patients with ACS \[[@B21-jcm-09-01657]\]. However, in the randomized clinical trials of the PHILO study with patients with ACS mainly recruited from Japan (*n* = 801) and the TICAKOREA trial with patients with ACS from Korea (*n* = 800), the major bleeding risk was higher, and ischemic events were lower in the aspirin plus ticagrelor group than in the aspirin plus clopidogrel group \[[@B22-jcm-09-01657],[@B23-jcm-09-01657]\].

However, the clinical experiences of ticagrelor use varied in other countries in Asia. The PRINCE trial was a randomized controlled study designed to compare the efficacy of aspirin plus ticagrelor with that of aspirin plus clopidogrel in 675 Chinese patients with minor ischemic stroke or transient ischemic attack. In patients with large artery atherosclerosis--related stroke, the ticagrelor/aspirin group had a lower stroke recurrence at 90 days than the clopidogrel/aspirin group, and no difference was observed in the rates of major or minor hemorrhagic events \[[@B24-jcm-09-01657]\]. In the real-world observation study of ACS treatment in Taiwan, DAPT with ticagrelor was associated with a lower risk of cardiovascular outcomes and did not increase the major bleeding compared with DAPT with clopidogrel \[[@B25-jcm-09-01657]\]. A study from Asia demonstrated that ticagrelor provides more potent platelet inhibition and suppresses more inflammatory reaction than clopidogrel \[[@B26-jcm-09-01657]\]. These results are consistent with those of a study from Europe \[[@B27-jcm-09-01657]\]. Although the major bleeding criteria were different among studies, the risk of major bleeding in the ticagrelor group in our study (approximately 3%) was roughly similar to that in the TICAKOREA trial (non-procedure- or CABG-related major bleeding 3.7%) \[[@B23-jcm-09-01657]\], the Korea real-world study (3.1%) \[[@B13-jcm-09-01657]\], and our previous observational study (major bleeding 3.2%) \[[@B25-jcm-09-01657]\]. Judicious and individualized use of P2Y12 inhibitor in real-world practice may reduce the bleeding risk in patients with ACS. The differences in the study results of ticagrelor in Japan and Korea remain unclear. The PHILO and TICAKOREA studies were not adequately powered to evaluate ticagrelor efficacy. For P2Y12 inhibitor monotherapy, we considered ticagrelor a better choice than clopidogrel because of its increased antiplatelet effect. In a subgroup analysis, ticagrelor showed significantly greater benefit than clopidogrel did in the diabetic group. Patients with both coronary artery disease and diabetes mellitus are at a high risk of ischemic events. In the THEMIS trial, patients with diabetes mellitus and stable coronary artery disease who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events than those who received aspirin monotherapy \[[@B28-jcm-09-01657]\]. Patients with diabetes have a high risk of ischemic cardiovascular events partly because of increased platelet activation, and ticagrelor provides increased potent platelet inhibition compared with clopidogrel. Besides, ticagrelor strongly inhibits toll-like receptor-1/2 and protease-activated receptor mediated platelet activation in patients with ACS. Off-target effects of ticagrelor might be one of potential mechanism for the reduction of adverse ischemic outcomes compared to clopidogrel \[[@B29-jcm-09-01657]\].

The relationship between bleeding and mortality is multifactorial, and bleeding is also a risk factor for ischemic outcomes in patients with ACS \[[@B30-jcm-09-01657]\]. Discontinuation of anti-platelet agents to manage bleeding is strongly associated with a higher risk of thrombotic events. Besides, after discontinuation of other optimal medications to correct hypotension after bleeding, such as angiotensin converting enzyme inhibitors or beta-blockers, these are not restarted after stable hemodynamics. For major bleeding events, administration of red blood cell transfusions or other blood products has been associated with increased platelet aggregation, thrombosis, systemic vasoconstriction, and activation of inflammatory pathways \[[@B30-jcm-09-01657]\]. In summary, bleeding is a complex challenge in patients with ACS.

The optimal antithrombotic strategy for patients with atrial fibrillation with ACS is another challenging issue. Dual therapy with oral anti-coagulant agent and P2Y12 inhibitor is standard choice, and clopidogrel has more clinical experiences and evidence due to concern with bleeding. In our retrospective database, similar trends were noted. The number of patients who needed oral anticoagulation was higher in the clopidogrel group than in the ticagrelor group. To eliminate the influence on clinical outcomes, IPTW propensity score method was used, involving covariate with atrial fibrillation. Besides, we also did another analysis with clinical outcomes after removing the patients need oral anticoagulation. In a comparison with 2 clinical outcome analyses with or without patients with oral anticoagulation, ticagrelor still had advantage in reducing ischemic events without increasing bleeding risk. Even with consistent results after comparison, our study was not primarily designed for solving these complicated issues. Further investigation is warranted to clarify these problems.

Our study had several limitations. First, our study was a retrospective, nonrandomized, observational study. The unadjusted confounding factors were unavoidable, even though a propensity-score-matched analysis was used to compensate for this. Second, although the major bleeding events defined as BARC 3 and 5 bleeding were similar between clopidogrel and ticagrelor groups, the risk of minor bleeding complications and other adverse effects of ticagrelor, such as dyspnea and bradycardia, was not recorded and could not be evaluated from this study. Besides, different reasons to stop aspirin might lead to different outcomes, especially when bleeding history was taken into account. Third, the number of patients who needed oral anticoagulation was more in the clopidogrel group than in the ticagrelor group. Dual therapy with clopidogrel and oral anticoagulation may influence clinical outcomes and increase bleeding risk. Therefore, we excluded the 122 patients with concomitant oral anticoagulation therapy from the analysis but found similar results ([Table 4](#jcm-09-01657-t004){ref-type="table"}). Fourth, BMS was used in approximately 40% of this cohort despite all guidelines recommending new-generation DES for ACS. In Taiwan, BMS was still commonly used because the Taiwan National Health Insurance only reimburses the price of BMS. The extra cost involved for DES has to be paid by patients themselves. However, the BMS distribution was similar between the groups and should not influence the clinical outcomes in our study. Finally, prasugrel was launched in Taiwan toward the end of 2018. Few prasugrel-treated ACS cases were noted during the study period, and therefore, we included only patients treated with clopidogrel or ticagrelor in this study. Further research is required to establish the efficacy and safety of prasugrel monotherapy.

For the retrospective nature of this study, we had difficulty in controlling the date of stopping aspirin among all enrolled patients. The interquartile range in ticagrelor group (1.00--55.00 days) was larger than in clopidogrel group (1.39--37.00 days). Residual effects of aspirin in the ticagrelor group might still be in these patients. Although our analysis indicated that there was no difference in the date of stopping aspirin, potential bias cannot be excluded completely. Besides, our results may not be applicable to non-Asian patients.

5. Conclusions {#sec5-jcm-09-01657}
==============

In patients with ACS undergoing PCI who cannot complete DAPT course aspirin, ticagrelor monotherapy resulted in substantially lower cardiovascular risk compared with clopidogrel monotherapy over a 1-year period. The major bleeding risk was similar between the groups. Because of the nature of the study design, our results are hypothesis-generating and must be reconfirmed by further randomized clinical trials.

The authors gratefully acknowledge the support of Kaohsiung Municipal Ta-Tung Hospital (kmtth-107-003). All enrolled patients were collected retrospectively from 8 major teaching hospitals in Taiwan: (1) National Cheng Kung University, Tainan, Taiwan; (2) Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; (3) Chang Gung Memorial Hospital, Taoyuan, Taiwan; (4) Chung Shan Medical University Hospital, Taichung, Taiwan; (5) MacKay Memorial Hospital, Taipei, Taiwan; (6) Changhua Christian Hospital, Changhua, Taiwan; (7) Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; (8) Tainan Municipal Hospital, Tainan, Taiwan. The deidentified participant data will be shared on request. Please contact the corresponding author directly for data.

Conceptualization, W.-H.F.; Data curation, P.-W.C., W.-H.F., M.-Y.H., C.-H.S., S.-W.H., C.-W.C., H.-I.Y., C.-P.C., W.-C.H., C.-C.F., I.-C.H. and Y.-H.L.; Formal analysis, P.-W.C., W.-H.F., H.-W.L. and S.-H.L.; Investigation, P.-W.C., M.-Y.H., C.-H.S., S.-W.H., C.-W.C., H.-I.Y., C.-P.C., W.-C.H., C.-C.F. and Y.-H.L.; Methodology, H.-W.L., S.-H.L. and Y.-H.L.; Project administration, W.-H.F. and Y.-H.L.; Software, H.-I.Y. and H.-W.L.; Supervision, S.-H.L. and I.-C.H.; Writing---original draft, P.-W.C., W.-H.F. and Y.-H.L.; Writing---review & editing, P.-W.C., W.-H.F. and Y.-H.L. All authors have read and agreed to the published version of the manuscript.

This research received no external funding.

The authors declare no conflict of interest.

![Subgroup analysis of the effect of clopidogrel versus ticagrelor on primary composite endpoint.](jcm-09-01657-g001){#jcm-09-01657-f001}

jcm-09-01657-t001_Table 1

###### 

Reasons for premature stop of aspirin.

  --------------------------------------------------------------------------------------------
                                         All\         Clopidogrel\   Ticagrelor\   *p*-Value
                                         *n* = 610    (*n* = 369)    (*n* = 241)   
  -------------------------------------- ------------ -------------- ------------- -----------
  Gastrointestinal bleeding              225 (36.9)   136 (36.9)     89 (36.9)     1.000

  Other site bleeding                    32 (5.3)     17 (4.6)       15 (6.2)      0.490

  Need oral anticoagulation              122 (20.0)   105 (28.5)     17 (7.1)      \<0.001

  Aspirin allergy or intolerance         52 (8.5)     23 (6.2)       29 (12.0)     0.018

  Gastrointestinal upset or discomfort   47 (7.7)     16 (4.3)       31 (12.9)     \<0.001

  Need surgery or thrombocytopenia       13 (2.1)     9 (2.4)        4 (1.7)       0.715

  Other or unknown causes                119 (19.5)   63 (17.1)      56 (23.2)     0.076
  --------------------------------------------------------------------------------------------

jcm-09-01657-t002_Table 2

###### 

Baseline characteristics of patients treated with clopidogrel versus ticagrelor.

                                                Inverse Probability of Treatment Weighting                                                      
  ------------------------------- ------------- -------------------------------------------- ------------- -------- ------------- ------------- ------
  Age                             70.4 ± 13.1   72.3 ± 13.1                                  67.4 ± 12.5   \<0.01   70.7 ± 18.3   70.6 ± 19.8   0.91
  Male                            440 (72.1)    66.7                                         80.5          \<0.01   71.6          72.8          0.80
  STEMI                           174 (28.5)    25.2                                         33.6          0.08     28.8          26.4          0.81
  Diabetes mellitus               323 (53.0)    52.3                                         53.9          0.75     54.7          58.1          0.48
  Hypertension                    462 (75.7)    80.0                                         69.3          \<0.01   77.6          78.0          0.91
  Hyperlipidemia                  328 (53.8)    54.7                                         52.3          0.61     53.3          49.0          0.38
  Smoker                          165 (27.1)    26.0                                         28.6          0.54     25.7          23.8          0.64
  Previous MI                     88 (14.4)     12.5                                         17.4          0.11     13.2          12.5          0.78
  Previous PCI                    160 (26.2)    22.5                                         32.0          0.01     24.6          23.8          0.84
  Previous CABG                   21 (3.4)      3.79                                         2.9           0.72     3.4           2.7           0.62
  Previous ischemic stroke        95 (15.6)     17.3                                         12.9          0.17     15.2          19.6          0.33
  Previous hemorrhagic stroke     6 (0.98)      1.4                                          0.4           0.41     1.3           0.6           0.38
  CKD without dialysis            227 (37.2)    39.3                                         34.0          0.22     38.8          42.6          0.45
  ESRD with dialysis              69 (11.3)     13.8                                         7.5           0.02     11.3          10.1          0.69
  Heart failure                   213 (34.9)    36.6                                         32.4          0.33     36.3          38.1          0.72
  Atrial fibrillation             160 (26.2)    35.0                                         12.9          \<0.01   26.6          25.2          0.77
  Peripheral artery disease       39 (6.4)      7.9                                          4.2           0.10     7.8           8.1           0.85
  LVEF                            56.5 ± 14.5   56.6 ± 14.7                                  56.4 ± 14.2   0.88     56.5 ± 18.9   56.5 ± 23.0   0.98
  CAG finding                                                                                              0.42                                 0.76
  1-vessel disease                158 (25.9)    27.6                                         23.2          0.26     26.4          26.8          0.94
  2-vessel disease                170 (27.9)    27.9)                                        27.8          1.00     26.3          29.1          0.53
  3-vessel disease                282 (46.2)    44.4                                         49.0          0.31     47.3          44.1          0.51
  PCI procedure                                                                                            0.19                                 0.98
  Single lesion intervention      341 (55.9)    53.7                                         59.3                   56.6          56.7          
  Multiple lesions intervention   269 (44.1)    46.3                                         40.7                   43.4          43.3          
  Location of lesion treated                                                                                                                    
  LM                              49 (8.0)      7.1                                          9.5           0.34     8.0           7.6           0.89
  LAD                             396 (64.9)    62.9                                         68.1          0.22     62.1          64.3          0.80
  LCX                             231 (37.9)    38.2                                         37.3          0.89     36.8          33.1          0.41
  RCA                             280 (45.9)    43.9                                         49.0          0.25     44.2          46.0          0.71
  SVG                             4 (0.7)       1.1                                          0             0.16     0             0             \-
  Stent                                                                                                                                         
  Bare metal stent                239 (39.2)    38.8                                         39.8          0.86     40.8          42.7          0.68
  Everolimus-eluting stent        130 (21.3)    22.5                                         19.5          0.43     21.9          23.8          0.68
  Zotarolimus-eluting stent       123 (20.2)    16.8                                         25.3          0.01     19.6          19.0          0.86
  Biolimus-eluting stent          29 (4.8)      4.1                                          5.8           0.43     3.9           4.1           0.92
  Siroliums-eluting stent         80 (13.1)     11.4                                         15.8          0.15     12.2          11.4          0.76
  Medications                                                                                                                                   
  Beta blocker                    443 (72.6)    70.2                                         76.4          0.12     73.3          72.9          0.93
  RAS inhibitor                   359 (58.9)    61.0                                         55.6          0.22     60.4          59.9          0.91
  Statin                          494 (81.0)    78.3                                         85.1          0.05     81.1          80.3          0.83
  PPI use                         252 (41.3)    48.8                                         29.9          \<0.01   41.6          37.8          0.43

Data are presented as number (percentages) or mean ± standard deviation. CABG, coronary artery bypass graft; CAG, coronary angiography; CKD, chronic kidney disease; ESRD, end stage renal disease; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main, LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; RAS, renin-angiotensin-aldosterone; RCA, right coronary artery; STEMI, ST-segment elevation myocardial infarction; SVG, saphenous vein graft.
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###### 

Clinical outcomes at 12-month follow-up.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
                                                 All\         Clopidogrel\   Ticagrelor\   Crude HR\           *p*-Value   Adjusted HR\        *p*-Value
                                                 *n* = 610    *n* = 369      *n* = 241     (95% CI)                        (95% CI)            
  ---------------------------------------------- ------------ -------------- ------------- ------------------- ----------- ------------------- -----------
  Primary composite endpoint                     84 (13.77)   57 (15.45)     27 (11.20)    0.66 (0.48--0.90)   0.008       0.67 (0.49--0.93)   0.018

  Secondary endpoint                                                                                                                           

  Recurrent ACS or unplanned revascularization   51 (8.36)    33 (8.94)      18 (7.47)     0.56 (0.36--0.86)   0.008       0.46 (0.28--0.75)   0.002

  Stroke                                         5 (0.82)     5 (1.36)       0 (0)         \-                  \-          \-                  \-

  All-cause death                                28 (4.59)    19 (5.15)      9 (3.73)      0.96 (0.60--1.53)   0.858       0.92 (0.52--1.61)   0.760

  BARC 3 or 5 bleeding                           25 (4.10)    18 (4.88)      7 (2.90)      0.86 (0.50--1.48)   0.574       0.71 (0.35--1.45)   0.345
  --------------------------------------------------------------------------------------------------------------------------------------------------------

ACS, acute coronary syndrome; BARC, Bleeding Academic Research Consortium.
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###### 

Clinical outcomes at 12-month follow-up after removing the patients need oral anticoagulation.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
                                                 All\         Clopidogrel\   Ticagrelor\   Crude HR\           *p*-Value   Adjusted HR\        *p*-Value
                                                 *n* = 488    *n* = 264      *n* = 224     (95% CI)                        (95% CI)            
  ---------------------------------------------- ------------ -------------- ------------- ------------------- ----------- ------------------- -----------
  Primary composite endpoint                     70 (14.34)   45 (17.05)     25 (11.16)    0.70 (0.50--0.97)   0.033       0.72 (0.51--1.03)   0.068

  Secondary endpoint                                                                                                                           

  Recurrent ACS or unplanned revascularization   44 (9.02)    27 (10.23)     17 (7.59)     0.58 (0.36--0.91)   0.019       0.50 (0.29--0.86)   0.013

  Stroke                                         1 (0.20)     1 (0.38)       0 (0.00)      \-                  \-          \-                  \-

  All-cause death                                25 (5.12)    17 (6.44)      8 (3.57)      0.93 (0.57--1.52)   0.764       0.68 (0.38--1.20)   0.185

  BARC 3 or 5 bleeding                           20 (4.10)    13 (4.92)      7 (3.13)      0.96 (0.51--1.83)   0.902       1.46 (0.65--3.29)   0.363
  --------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: These authors contributed equally to this work.
